Human TBK1: A Gatekeeper of Neuroinflammation

Trends in Molecular Medicine

Volumn 22, Issue 6, 2016, Pages 511-527

  Ahmad, Liyana ^a   Zhang, Shen Ying ^b,c,d   Casanova, Jean Laurent ^b,c,d,e,f   Sancho Shimizu, Vanessa ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ROCKEFELLER UNIVERSITY   (United States)

^c IMAGINE INSTITUTE   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Amyotrophic lateral sclerosis; Autophagy; Dementia; Glaucoma; Herpes simplex encephalitis; Interferon; TBK1

Indexed keywords

DNA BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; PATTERN RECOGNITION RECEPTOR; PHOSPHOTRANSFERASE; TANK BINDING KINASE 1; TAR DNA BINDING PROTEIN; TOLL LIKE RECEPTOR 3; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; VIRUS DNA; PROTEIN SERINE THREONINE KINASE; TBK1 PROTEIN, HUMAN;

AMYOTROPHIC LATERAL SCLEROSIS; AUTOPHAGY; CELLULAR DISTRIBUTION; CYTOKINE PRODUCTION; FRAMESHIFT MUTATION; FRONTOTEMPORAL DEMENTIA; GAIN OF FUNCTION MUTATION; GENE DELETION; GENE DUPLICATION; GENE MUTATION; GENETIC PREDISPOSITION; HERPES SIMPLEX ENCEPHALITIS; HERPES SIMPLEX VIRUS 1; HUMAN; LOSS OF FUNCTION MUTATION; LOW TENSION GLAUCOMA; MACROPHAGE; MISSENSE MUTATION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOGENESIS; PATHOGENICITY; REVIEW; CENTRAL NERVOUS SYSTEM; DISEASE COURSE; GENE EXPRESSION; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM; MUTATION;

AMYOTROPHIC LATERAL SCLEROSIS; AUTOPHAGY; CENTRAL NERVOUS SYSTEM; DISEASE PROGRESSION; ENCEPHALITIS, HERPES SIMPLEX; FRONTOTEMPORAL DEMENTIA; GENE EXPRESSION; HUMANS; INFLAMMATION; INTERFERONS; LOW TENSION GLAUCOMA; MUTATION; PROTEIN-SERINE-THREONINE KINASES;

EID: 84970004915     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.04.006     Document Type: Review

References (116)

1. Fitzgerald K.A., et al. IKKe and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 2003, 4:491-496.
2. Thurston T.L.M., et al. The TBK1 adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitin-coated bacteria. Nat. Immunol. 2009, 10:1215-1221.
3. Wild P., et al. Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth. Science 2011, 333:228-233.
4. Pilli M., et al. TBK-1 promotes autophagy-mediated antimicrobial defense by controlling autophagosome maturation. Immunity 2012, 37:223-234.
5. Clément J-F., et al. The IKK-related kinases: from innate immunity to oncogenesis. Cell Res. 2008, 18:889-899.
6. Herman M., et al. Heterozygous TBK1 mutations impair TLR3 immunity and underlie herpes simplex encephalitis of childhood. J. Exp. Med. 2012, 209:1567-1582.
7. Cirulli E.T., et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 2015, 347:1436-1441.
8. Freischmidt A., et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 2015, 18:631-636.
9. Pottier C., et al. Whole-genome sequencing reveals important role for TBK1 and OPTN mutations in frontotemporal lobar degeneration without motor neuron disease. Acta Neuropathol. 2015, 130:77-92.
10. Fingert J.H., et al. Copy number variations on chromosome 12q14 in patients with normal tension glaucoma. Hum. Mol. Genet. 2011, 20:2482-2494.
11. Gijselinck I., et al. Loss of TBK1 is a frequent cause of frontotemporal dementia in a Belgian cohort. Neurology 2015, 85:2116-2125.
12. Pomerantz J.L., Baltimore D. NF-κB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J. 1999, 18:6694-6704.
13. Tojima Y., et al. NAK is an IκB kinase-activating kinase. Nature 2000, 404:778-782.
14. Chau T-L., et al. Are the IKKs and IKK-related kinases TBK1 and IKK-e similarly activated?. Trends Biochem. Sci. 2008, 33:171-180.
15. Sharma S., et al. Triggering the interferon antiviral response through an IKK-related pathway. Science 2003, 300:1148-1151.
16. Yamamoto M., et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003, 301:640-643.
17. Loo Y-M., Gale M. Immune signaling by RIG-I-like receptors. Immunity 2011, 34:680-692.
18. Ishii K.J., et al. A toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat. Immunol. 2006, 7:40-48.
19. Paz S., et al. Induction of IRF-3 and IRF-7 phosphorylation following activation of the RIG-I pathway. Cell. Mol. Biol. (Noisy-le-grand) 2006, 52:17-28.
20. Sun L., et al. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 2013, 339:786-791.
21. Saitoh T., et al. Atg9a controls dsDNA-driven dynamic translocation of STING and the innate immune response. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:20842-20846.
22. Ishikawa H., Barber G.N. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 2008, 455:674-678.
23. Kumar H., et al. Pathogen recognition in the innate immune response. Biochem. J. 2009, 420:1-16.
24. Soulat D., et al. The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response. EMBO J. 2008, 27:2135-2146.
25. Klionsky D.J. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat. Rev. Mol. Cell Biol. 2007, 8:931-937.
26. Klionsky D.J., Schulman B.A. Dynamic regulation of macroautophagy by distinctive ubiquitin-like proteins. Nat. Struct. Mol. Biol. 2014, 21:336-345.
27. Stolz A., et al. Cargo recognition and trafficking in selective autophagy. Nat. Cell Biol. 2014, 16:495-501.
28. Kirkin V., et al. A role for NBR1 in autophagosomal degradation of ubiquitinated substrates. Mol. Cell 2009, 33:505-516.
29. Matsumoto G., et al. Serine 403 phosphorylation of p62/SQSTM1 regulates selective autophagic clearance of ubiquitinated proteins. Mol. Cell 2011, 44:279-289.
30. Mostowy S., et al. p62 and NDP52 proteins target intracytosolic Shigella and Listeria to different autophagy pathways. J. Biol. Chem. 2011, 286:26987-26995.
31. Komatsu M., et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 2006, 441:880-884.
32. Hara T., et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006, 441:885-889.
33. Korac J., et al. Ubiquitin-independent function of optineurin in autophagic clearance of protein aggregates. J. Cell Sci. 2013, 126:580-592.
34. Morton S., et al. Enhanced binding of TBK1 by an optineurin mutant that causes a familial form of primary open angle glaucoma. FEBS Lett. 2008, 582:997-1002.
35. Lussignol M., et al. The herpes simplex virus 1 Us11 protein inhibits autophagy through its interaction with the protein kinase PKR. J. Virol. 2013, 87:859-871.
36. Chou J., et al. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990, 250:1262-1266.
37. Orvedahl A., et al. HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. Cell Host Microbe 2007, 1:23-35.
38. Ma Y., et al. Inhibition of TANK binding kinase 1 by herpes simplex virus 1 facilitates productive infection. J. Virol. 2012, 86:2188-2196.
39. Liang Q., et al. Crosstalk between the cGAS DNA sensor and Beclin-1 autophagy protein shapes innate antimicrobial immune responses. Cell Host Microbe 2014, 15:228-238.
40. Watson R.O., et al. The cytosolic sensor cGAS detects Mycobacterium tuberculosis DNA to induce type i interferons and activate autophagy. Cell Host Microbe 2015, 17:811-819.
41. Whitley R.J., Gnann J.W. Viral encephalitis: familiar infections and emerging pathogens. Lancet 2002, 359:507-513.
42. Abel L., et al. Age-dependent Mendelian predisposition to herpes simplex virus type 1 encephalitis in childhood. J. Pediatr. 2010, 157:623-629.
43. De Tiège X., et al. The spectrum of herpes simplex encephalitis in children. Eur. J. Paediatr. Neurol. 2008, 12:72-81.
44. Lahat E., et al. Long term neurological outcome of herpes encephalitis. Arch. Dis. Child. 1999, 80:69-71.
45. Whitley R.J., et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N. Engl. J. Med. 1986, 314:144-149.
46. Zhang S-Y., et al. TLR3 immunity to infection in mice and humans. Curr. Opin. Immunol. 2013, 25:19-33.
47. Casrouge A., et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 2006, 314:308-312.
48. Zhang S-Y., et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007, 317:1522-1527.
49. Guo Y., et al. Herpes simplex virus encephalitis in a patient with complete TLR3 deficiency: TLR3 is otherwise redundant in protective immunity. J. Exp. Med. 2011, 208:2083-2098.
50. Sancho-Shimizu V., et al. Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J. Clin. Invest. 2011, 121:4889-4902.
51. Pérez de Diego R., et al. Human TRAF3 adaptor molecule deficiency leads to impaired toll-like receptor 3 response and susceptibility to herpes simplex encephalitis. Immunity 2010, 33:400-411.
52. Andersen L.L., et al. Functional IRF3 deficiency in a patient with herpes simplex encephalitis. J. Exp. Med. 2015, 212:1371-1379.
53. Zhang S-Y., et al. Mendelian predisposition to herpes simplex encephalitis. Handb. Clin. Neurol. 2013, 112:1091-1097.
54. Lafaille F.G., et al. Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature 2012, 491:769-773.
55. Alexopoulou L., et al. Recognition of double-stranded RNA and activation of NF-κB by toll-like receptor 3. Nature 2001, 413:732-738.
56. Weber F., et al. Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J. Virol. 2006, 80:5059-5064.
57. Jacquemont B., Roizman B. Ribonucleic acid synthesis in cells infected with herpes simplex virus: characterization of viral high molecular weight nuclear RNA. J. Gen. Virol. 1975, 29:155-165.
58. Balachandran S., et al. Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/caspase-8 death signaling pathway. J. Virol. 2000, 74:1513-1523.
59. Shaw P.J. Molecular and cellular pathways of neurodegeneration in motor neurone disease. J. Neurol. Neurosurg. Psychiatry 2005, 76:1046-1057.
60. Charcot J-M., Joffroy A. Deux cas d'atrophie musculaire progressive avec lésions de la substance grise et des faiseaux antéro-latéraux de la moelle épinière. Arch. Physiol. Norm. Pathol. 1869, 2:744-760. (in French).
61. Rowland L.P., Shneider N.A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2001, 344:1688-1700.
62. Barber S.C., et al. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim. Biophys. Acta 2006, 1762:1051-1067.
63. Shi P., et al. Mitochondrial dysfunction in amyotrophic lateral sclerosis. Biochim. Biophys. Acta 2010, 1802:45-51.
64. Hirano A., et al. Fine structural observations of neurofilamentous changes in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 1984, 43:461-470.
65. Zhao W., et al. Immune-mediated mechanisms in the pathoprogression of amyotrophic lateral sclerosis. J. Neuroimmune Pharmacol. 2013, 8:888-899.
66. Lomen-Hoerth C., et al. The overlap of amyotrophic lateral sclerosis and frontotemporal dementia. Neurology 2002, 59:1077-1079.
67. Neumann M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006, 314:130-133.
68. Rosen D.R., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
69. Sreedharan J., et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008, 319:1668-1672.
70. Kwiatkowski T.J., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009, 323:1205-1208.
71. Deng H-X., et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011, 477:211-215.
72. Renton A.E., et al. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 2014, 17:17-23.
73. Maruyama H., et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010, 465:223-226.
74. Khoris J., et al. Coexistence of dominant and recessive familial amyotrophic lateral sclerosis with the D90A Cu,Zn superoxide dismutase mutation within the same country. Eur. J. Neurol. 2000, 7:207-211.
75. Hand C.K., et al. Compound heterozygous D90A and D96N SOD1 mutations in a recessive amyotrophic lateral sclerosis family. Ann. Neurol. 2001, 49:267-271.
76. Hadano S., et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet. 2001, 29:166-173.
77. Fecto F. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch. Neurol. 2011, 68:1440.
78. Le Ber I., et al. TBK1 mutation frequencies in French frontotemporal dementia and amyotrophic lateral sclerosis cohorts. Neurobiol. Aging 2015, 36. 3116.e5-3116.e8.
79. Williams K.L., et al. Novel TBK1 truncating mutation in a familial amyotrophic lateral sclerosis patient of Chinese origin. Neurobiol. Aging 2015, 36. 3334.e1-3334.e5.
80. Quigley H.A. Glaucoma. Lancet 2011, 377:1367-1377.
81. Friedman D.S., et al. Prevalence of open-angle glaucoma among adults in the United States. Arch. Ophthalmol. 2004, 122:532-538.
82. Quigley H.A. Glaucoma. Lancet 2011, 377:1367-1377.
83. Minegishi Y., et al. Enhanced optineurin E50K-TBK1 interaction evokes protein insolubility and initiates familial primary open-angle glaucoma. Hum. Mol. Genet. 2013, 22:3559-3567.
84. Fingert J.H. Primary open-angle glaucoma genes. Eye (Lond.) 2011, 25:587-595.
85. Kawase K., et al. Confirmation of TBK1 duplication in normal tension glaucoma. Exp. Eye Res. 2012, 96:178-180.
86. Ritch R., et al. TBK1 gene duplication and normal-tension glaucoma. JAMA Ophthalmol. 2014, 132:544-548.
87. Exome Aggregation Consortium, et al. Analysis of protein-coding genetic variation in 60,706 humans. 2015, Cold Spring Harbor Laboratory, Published online October 30, 2015. http://dx.doi.org/10.1101/030338.
88. Casanova J-L., et al. Immunology taught by human genetics. Cold Spring Harb. Symp. Quant. Biol. 2013, 78:157-172.
89. Goncalves A., et al. Functional dissection of the TBK1 molecular network. PLoS One 2011, 6:e23971.
90. Yordy B., et al. A neuron-specific role for autophagy in antiviral defense against herpes simplex virus. Cell Host Microbe 2012, 12:334-345.
91. Looker K.J., et al. Global and regional estimates of prevalent and incident herpes simplex virus type 1 infections in 2012. PLoS One 2015, 10:e0140765.
92. Yang Y., et al. Clinical whole-exome sequencing for the diagnosis of Mendelian disorders. N. Engl. J. Med. 2013, 369:1502-1511.
93. Lee H., et al. Clinical exome sequencing for genetic identification of rare Mendelian disorders. JAMA 2014, 312:1880-1887.
94. Casanova J-L. Severe infectious diseases of childhood as monogenic inborn errors of immunity. Proc. Natl Acad. Sci. U.S.A. 2015, 112:E7128-E7137.
95. Zhu X., et al. One gene, many neuropsychiatric disorders: lessons from Mendelian diseases. Nat. Neurosci. 2014, 17:773-781.
96. Boisson-Dupuis S., et al. Inborn errors of human STAT1: allelic heterogeneity governs the diversity of immunological and infectious phenotypes. Curr. Opin. Immunol. 2012, 24:364-378.
97. Li J., et al. Crystal structure of the ubiquitin-like domain of human TBK1. Protein Cell 2012, 3:383-391.
98. Zhang K.Y., et al. Ubiquilin 2: a component of the ubiquitin-proteasome system with an emerging role in neurodegeneration. Int. J. Biochem. Cell Biol. 2014, 50:123-126.
99. Bonnard M., et al. Deficiency of T2K leads to apoptotic liver degeneration and impaired NF-κB-dependent gene transcription. EMBO J. 2000, 19:4976-4985.
100. Marchlik E., et al. Mice lacking Tbk1 activity exhibit immune cell infiltrates in multiple tissues and increased susceptibility to LPS-induced lethality. J. Leukoc. Biol. 2010, 88:1171-1180.
101. McWhirter S.M., et al. IFN-regulatory factor 3-dependent gene expression is defective in Tbk1-deficient mouse embryonic fibroblasts. Proc. Natl Acad. Sci. U.S.A. 2004, 101:233-238.
102. Miyahira A.K., et al. TANK-binding kinase-1 plays an important role during in vitro and in vivo type I IFN responses to DNA virus infections. J. Immunol. 2009, 182:2248-2257.
103. Perry A.K., et al. Differential requirement for TANK-binding kinase-1 in type I interferon responses to toll-like receptor activation and viral infection. J. Exp. Med. 2004, 199:1651-1658.
104. Wang R., et al. Activation of interferon signaling pathways in spinal cord astrocytes from an ALS mouse model. Glia 2011, 59:946-958.
105. Hofer M.J., et al. The type I interferon-αalpha mediates a more severe neurological disease in the absence of the canonical signaling molecule interferon regulatory factor 9. J. Neurosci. 2010, 30:1149-1157.
106. van Boxel-Dezaire A.H.H., et al. Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 2006, 25:361-372.
107. Mankouri J., et al. Optineurin negatively regulates the induction of IFNβ in response to RNA virus infection. PLoS Pathog. 2010, 6:e1000778.
108. Sakaguchi T., et al. Optineurin with amyotrophic lateral sclerosis-related mutations abrogates inhibition of interferon regulatory factor-3 activation. Neurosci. Lett. 2011, 505:279-281.
109. Mattson M.P., Meffert M.K. Roles for NF-κB in nerve cell survival, plasticity, and disease. Cell Death Differ. 2006, 13:852-860.
110. Weinreb R.N., et al. The pathophysiology and treatment of glaucoma: a review. JAMA 2014, 311:1901-1911.
111. Elion G.B. The biochemistry and mechanism of action of acyclovir. J. Antimicrob. Chemother. 1983, 12(Suppl. B):9-17.
112. Miller R.G., et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. 2007, 3:CD001447.
113. de Paula C.Z., et al. An overview of potential targets for treating amyotrophic lateral sclerosis and Huntington's disease. Biomed Res. Int. 2015, 2015:1-7.
114. Sambhara D., Aref A.A. Glaucoma management: relative value and place in therapy of available drug treatments. Ther. Adv. Chronic Dis. 2014, 5:30-43.
115. Bamshad M.J., et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat. Rev. Genet. 2011, 12:745-755.
116. Itan Y. The human gene damage index as a gene-level approach to prioritizing exome variants. Proc. Natl Acad. Sci. U.S.A. 2015, 112:13615-13620.